PAUL MILLER: Open Payments
NPI 1447561998 · BINGHAMTON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,194 in 56 payments from 8 companies in 2025. Trend: 2023 $925 · 2024 $1,457 · 2025 $2,194
Food & beverage: $2,194
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $969 |
| Neurocrine BioSciences, Inc. | 5 | $304 |
| Alkermes, Inc. | 3 | $256 |
| Axsome Therapeutics, Inc. | 2 | $242 |
| E.R. Squibb & Sons, L.L.C. | 11 | $147 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $127 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Biogen, Inc. | 1 | $24 |
Products named: VRAYLAR, INGREZZA, Auvelity, COBENFY, ARISTADA, CAPLYTA, FANAPT, LYBALVI.
Industry payments across NY — which companies pay providers there.
